Molecure Dividends and Buybacks

Dividend criteria checks 0/6

Molecure does not have a record of paying a dividend.

Key information

n/a

Dividend yield

Buyback Yield

Total Shareholder Yield	0%
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Feb 24

Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

Jan 02

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if MOC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MOC's dividend payments have been increasing.

Dividend Yield vs Market

Molecure Dividend Yield vs Market

How does MOC dividend yield compare to the market?
Segment	Dividend Yield
Company (MOC)	n/a
Market Bottom 25% (PL)	2.8%
Market Top 25% (PL)	7.9%
Industry Average (Pharmaceuticals)	2.6%
Analyst forecast (MOC) (up to 3 years)	n/a

Notable Dividend: Unable to evaluate MOC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MOC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate MOC's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MOC has not reported any payouts.

Molecure Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

New minor risk - Profitability

Price target decreased by 22% to zł23.25

Second quarter 2024 earnings released: zł0.46 loss per share (vs zł0.29 loss in 2Q 2023)

Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

New major risk - Revenue and earnings growth

New minor risk - Financial position

No longer forecast to breakeven

Molecure S.A. Receives Approval to Initiate A Phase II Clinical Trial (KITE) for OATD-01 for the Treatment of Pulmonary Sarcoidosis in Selected Countries of the European Union and Norway

Molecure S.A., Annual General Meeting, Jun 13, 2024

New minor risk - Financial data availability

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis

Molecure S.A. to Report Q3, 2024 Results on Oct 31, 2024

New major risk - Revenue and earnings growth

Molecure S.A Announces No Grant of Permission to Conduct Phase II Clinical Trials for the OATD-01 Molecule I

We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Third quarter 2023 earnings released: zł0.25 loss per share (vs zł0.16 loss in 3Q 2022)

Second quarter 2023 earnings released

New minor risk - Share price stability

New minor risk - Shareholder dilution

Molecure S.A. Receives Clearance from the U.S. Food and Drug Administration on its Investigational New Drug Application to Conduct Phase II Clinical Testing of OATD-01

Molecure S.A. announced that it has received PLN 49.968 million in funding

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Molecure S.A., Annual General Meeting, May 31, 2023

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Molecure S.A. to Report Q1, 2023 Results on Apr 28, 2023

Molecure S.A. Announces Management Changes

Molecure S.A. to Begin Clinical Development of Novel Dual Arginase Inhibitor Oatd-02 for the Treatment of Cancer After Gaining Permission to Conduct First Clinical Trial in Poland

Third quarter 2022 earnings released: zł0.16 loss per share (vs zł0.13 loss in 3Q 2021)

Second quarter 2022 earnings released: zł0.27 loss per share (vs zł0.20 loss in 2Q 2021)

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Molecure S.A., Annual General Meeting, Jun 30, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

OncoArendi Therapeutics S.A. Announces Board Appointments

OncoArendi Therapeutics S.A Appoints Samson Fung as Chief Medical Officer

OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Second quarter 2021 earnings released: zł0.21 loss per share (vs zł0.034 loss in 2Q 2020)

CEO & President of Management Board recently bought zł178k worth of stock

Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

OncoArendi Therapeutics S.A. to Report Q2, 2021 Results on Sep 27, 2021

Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

New 90-day high: zł57.80

OncoArendi Therapeutics SA and Galapagos Enter into Exclusive Collaboration on Chitinase Inhibitors in Fibrosis

Third quarter 2020 earnings released: zł0.06 loss per share

First half earnings released

New 90-day high - zł19.70

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies